# A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)

> **NCT03305809** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 344 (actual)

## Conditions studied

- Lewy Body Dementia

## Interventions

- **DRUG:** LY3154207
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03305809
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-09
- **Primary completion:** 2020-07-10
- **Final completion:** 2020-07-10
- **Target enrollment:** 344 (ACTUAL)
- **Last updated:** 2021-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03305809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03305809, "A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03305809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*